| R-CHOP or R-HyperCVAD W/O autologous stem cell transplantation |
Chemo-immunotherapy |
older patients with MCL |
R-HyperCVAD > toxicity (infection, venous thrombosis, acute kidey injury, transfusion need) than R-CHOP |
38 |
N/A |
N/A |
N/A |
N/A |
N/A |
R-CHOP + ASCT: 3.2 Y R-HyperCVAD: 4 Y R-CHOP:1.6 Y |
2015 |
[46] |
| Bendamustine-Rituximab (BR) Vs R-CHOP/R-CVP |
B: mechlorethamine R:monoconal Ab R-CHOP/R-CVP: Chemoimmunotherapy |
first-line treatment of indolent NHL or MCL |
vomiting, drug-hypersensitivity reactions higher in patients treated with BR & peripheral neuropathy /paresthesia and alopecia higher in patients treated with R-CHOP/R-CVP |
BR:224 R-CHOP/RCVP:223 |
3 |
BR:31% R-CHOP/R-CVP:25% |
N/A |
N/A |
97% Vs. 91% |
N/A |
2014 |
[98] |
| Lenalidomide and Rituximab |
Lenalidomide:immuno-modulatory agent, rituximab: anti-CD20 mAb |
indolent B-cell or mantle cell lymphomas previously rituximab resistant |
N/A |
50, evaluable:43 |
2 |
N/A |
N/A |
N/A |
L: 30.2%, L+R: 62.8% |
22.2 months |
2014 |
[21] |
| HyperCVAD MTX/Ara-C and rituximab |
Chemo-immunotherapy |
previously untreated MCL |
One death secondary to myelodysplastic syndrome, grade 3 febrile neutropenia & grade 4 infection |
49 |
2 |
47% |
31% |
6.8 Y |
86% |
4.8 Y |
2013 |
[53] |
| CHOP &DHAP + rituximab followed by autologous stem cell transplantation |
Chemo-immunotherapy |
younger patients with MCL |
No toxic death or unexpected toxicities |
60 |
2 |
RCHOP: 12% R-DHAP:57% |
N/A |
Five Y 75% |
(R)-CHOP:93% and R-DHAP:95% |
83 months |
2013 |
[47] |
| Bendamustine +Rituximab + Cytarabine (R-BAC) |
Alkylating agent + anti-CD20 monoclonal antibody + anti-metabolite |
untreated (A1) or relapsed or refractory (R/R) MCL (A2) |
grades 3 to 4 thrombocytopenia (87% of patients) and febrile neutropenia occurred in 12% |
40 |
2 |
A1:95% A2:70% |
N/A |
N/A |
A1:100% A2: 80% |
A1: 2-years was 95% ± 5%; 70% ± 10% for A2 |
2013 |
[118] |
| Bendamustine + Rituximab (A1) Vs. CHOP plus Rituximab(A2) |
Alkylating agent + monoconal Ab Vs. Chemoimmunotherapy |
first-line treatment for patients with indolent and MCL |
haematological toxicity, infections, peripheral neuropathy, and stomatitis |
A1:274(assessed: 261), A2: 275 (assessed:253) |
3 |
N/A |
N/A |
N/A |
N/A |
A1:69.5 months, A2: 31.2 months |
2012 |
[23] |
| rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) |
Chemoimmunotherapy+ Proteosome inhibitor |
first line treatment for elderly MCL patients |
(18%) experienced grade 3 neurotoxicity |
39 |
2 |
0.51 |
N/A |
N/A |
79% |
26 months |
2012 |
[49] |
| R-CHOP followed by yttrium-90 (90Y) –ibritumomab tiuxetan |
Chemoimmunotherapy followed by radioimmunotherapy |
untrreated MCL pateients |
no unexpected toxicities |
56 patients were eligible |
2 |
55% |
N/A |
N/A |
82% |
N/A |
2012 |
[48] |
| Chlorambucil + Rituximab |
Alkylating agent + monoconal Ab |
Indolent MCL |
No serious side effects |
20 |
N/A |
0.9 |
0.05 |
N/A |
0.95 |
89% had 3 years PFS |
2011 |
[252] |
| Bortezomib plus CHOP-Rituximab |
proteasome inhibitor+ Chemoimmunotherapy |
previously untreated DLBCL and MCL |
neuropathy, grade 3/4 anemia, neutropenia & thrombocytopenia |
76 |
1/2 |
DLBCL:86% MCL:72% |
N/A |
2Y DLBCL:70% 2Y MCL:86% |
DLBCL:100% MCL:91% |
2 Y DLBCL:64% 2 Y MCL: 44% |
2011 |
[253] |
| R-HyperCVAD alternating with R-MA & without stem cell transplantation |
Intense chemoimmunotherapy |
untreated aggressive MCL |
myelodysplasia/acute myelogenous leukemia, acute toxicity +8 deaths |
97 |
2 |
87% |
N/A |
10Y:not-reached, 8Y:56% |
97% |
N/A |
2010 |
[106] |
| (R)VAD+C |
Chemoimmunotherapy |
Newly Diagnosed MCL |
very low hematologic toxicity |
113 |
2 |
65% at end of treatment |
N/A |
N/A |
73% |
N/A |
2010 |
[254] |
| CTAP alternating with VMAC |
Intensive multiagent chemotherapeutic regimen |
newly diagnosed MCL |
well-tolerated with 4% treatment-related mortality (including HSCT) |
25 |
2 |
N/A |
N/A |
5Y: 75% |
74% |
5 Y: 54% |
2008 |
[255] |
| Fostamatinib |
prodrug of the spleen tyrosine kinase (Syk) inhibitor R-406 |
MCl & other B cell lymphomas |
neutropenia, diarrhea, and thrombocytopenia |
60 |
1&2 |
NA |
N/A |
N/A |
11% (1/9) for MCL |
4.2 months |
2007 |
[256] |
| Bendamustine, Vincristine + Prednisone (BOP) Vs. Cyclophosphamide, Vincristine + Prednisone (COP) |
Chemotherapy |
advanced indolent NHL and MCL |
alopecia and leucopenia were more severe with COP. |
164 |
3 |
BOP:22% COP:20% |
N/A |
N/A |
BOP:61% COP:46% |
N/A |
2006 |
[257] |
| CHOP vs R-CHOP |
chemotherapy Vs. chemoimmunotherapy |
previously untreated patients with advanced-stage MCL |
Acceptable, with no major differences between the two therapeutic groups. |
122 |
3 |
7% Vs 34% |
N/A |
N/A |
75% Vs. 94% |
N/A |
2005 |
[114] |
| R-HyperCVAD alternating with rituximab plus high-dose methotrexate and cytarabine. |
chemoimmunotherapy |
untreated aggressive Stage III/IV MCL |
myelodysplasia/acute myelogenous leukemia & eight treatment-related deaths |
97 |
2 |
87% |
10% |
3Y: 82% |
97% |
3 Y: 64% |
2005 |
[258] |
| Intensive chemotherapy (A1) Vs. (ASCT) and rituximab(A2) |
R: immunotherapy |
stage III/IV MCL |
febrile neutropenia, Mucositis, interstitial pneumonitis & herpes zoster |
20 |
2 |
N/A |
N/A |
OS: 3Y A1: 65% A2:88% |
N/A |
A1: 29% A2:89% |
2004 |
[259] |
| Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation |
chemotherapy |
aggressive Stage III/IV |
Treatment-related death occurred in five patients |
45 |
N/A |
38% |
55.50% |
N/A |
93.50% |
3 Y |
1998 |
[130] |
